Neisseria meningitidis polysaccharide conjugated to tetanus toxoid
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2012
- First approval year
- 2012
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Neisseria meningitidis polysaccharide conjugated to tetanus toxoid
- menquadfi
- Menquadfi
- neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen component of penbraya
- Neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen component of penbraya
- neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen component of penbraya
- Neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen component of penbraya
- neisseria meningitidis group w 135 capsular polysaccharide tetanus toxoid conjugate antigen component of penbraya
- Neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conjugate antigen component of penbraya
- neisseria meningitidis group y capsular polysaccharide tetanus toxoid conjugate antigen component of penbraya
- Neisseria meningitidis group y capsular polysaccharide tetanus toxoid conjugate antigen component of penbraya
- nimenrix
- Nimenrix
- gsk biolgicals meningococcal vaccine 134612 nimenrix
- GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)
- GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)
- Meningococcal vaccine GSK134612 (Nimenrix)
- neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen
- Neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen
- neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen
- Neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen
- neisseria meningitidis group w 135 capsular polysaccharide tetanus toxoid conjugate antigen
- Neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conjugate antigen
- neisseria meningitidis group y capsular polysaccharide tetanus toxoid conjugate antigen
- Neisseria meningitidis group y capsular polysaccharide tetanus toxoid conjugate antigen
- neisseria meningitidis polysaccharide conjugated to tetanus toxoid
- Neisseria meningitidis polysaccharide conjugated to tetanus toxoid
- Nimenrix
- Nimenrix (GSK134612 vaccine)
- Nimenrix (Meningococcal vaccine 134612)
- Nimenrix™
- ChEMBL ID
- CHEMBL6068498
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Polysaccharide conjugated to Tetanus toxoid vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Polysaccharide conjugated to Tetanus toxoid
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Meningitis, Meningococcal
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001040
- Subject identifier
- D008585
- Condition identifier
- EFO_0000584
- Condition identifier
- EFO_0004249
- Condition identifier
- MONDO_0004796
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005373
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0018059
- Highest recorded phase
- 4
- Event
- asthenia
- Reports
- 7
- Reporting signal score
- 17.4282
- Event
- eosinophilia
- Reports
- 5
- Reporting signal score
- 22.7049
- Event
- generalised oedema
- Reports
- 5
- Reporting signal score
- 26.037
- Event
- hyperpyrexia
- Reports
- 7
- Reporting signal score
- 45.9842
- Event
- rash erythematous
- Reports
- 5
- Reporting signal score
- 20.6845
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (34)
- A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
- A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
- A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age
- Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
- Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine
- Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
- Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children
- Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects
- Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
- Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines
- Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
- Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
- Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults
- Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults
Approved for (1)
Other linked conditions (2)
- Infectious meningitis
- Meningococcal infection